Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
27.70
-0.10 (-0.36%)
At close: Mar 20, 2026, 4:00 PM EDT
28.40
+0.70 (2.51%)
After-hours: Mar 20, 2026, 7:44 PM EDT
Roivant Sciences Revenue
Roivant Sciences had revenue of $2.00M in the quarter ending December 31, 2025, a decrease of -77.83%. This brings the company's revenue in the last twelve months to $13.31M, down -56.36% year-over-year. In the fiscal year ending March 31, 2025, Roivant Sciences had annual revenue of $29.05M, down -11.19%.
Revenue (ttm)
$13.31M
Revenue Growth
-56.36%
P/S Ratio
1,489.48
Revenue / Employee
$17,747
Employees
750
Market Cap
19.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 29.05M | -3.66M | -11.19% |
| Mar 31, 2024 | 32.71M | 1.18M | 3.75% |
| Mar 31, 2023 | 31.53M | -23.76M | -42.97% |
| Mar 31, 2022 | 55.29M | 31.49M | 132.34% |
| Mar 31, 2021 | 23.80M | -43.89M | -64.85% |
| Mar 31, 2020 | 67.69M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 5.34B |
| Incyte | 5.14B |
| Genmab | 3.72B |
| BioNTech SE | 3.37B |
| Royalty Pharma | 2.38B |
| Moderna | 1.94B |
| Ascendis Pharma | 845.52M |
| Insmed | 606.42M |
ROIV News
- 10 days ago - Roivant Sciences Ltd. (ROIV) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 17 days ago - Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation Transcript - Seeking Alpha
- 17 days ago - Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute - Reuters
- 17 days ago - Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna - GlobeNewsWire
- 17 days ago - Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewsWire
- 17 days ago - Roivant Sciences Ltd. (ROIV) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 18 days ago - Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis - GlobeNewsWire
- 6 weeks ago - Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade) - Seeking Alpha